EUVIMEDEUVIMED entdecken
Open Access

Homologous recombination repair germline variants and subsequent neoplasm risk among childhood cancer survivors

Shahriar A Zamani iD, Danielle M Karyadi iD, Stephen W Hartley iD, Todd M Gibson iD, Joshua N Sampson iD, Peter Kraft iD, Stephen J Chanock iD, Lindsay M Morton iD

JNCI Cancer Spectrum · 09.05.2026 · 10 (3)

DOI: 10.1093/jncics/pkag030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 21.03.2026. Verfasst von Shahriar A Zamani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, United States. Hauptthemen laut MEDLINE: Germ-Line Mutation, Recombinational DNA Repair, Neoplasms, Radiation-Induced, Neoplasms, Second Primary. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Center Support Grants, US Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Childhood cancer radiation therapy (RT) increases subsequent neoplasm risk. Radiation dose may modulate DNA damage responses, but the small sample sizes of prior human studies of homologous recombination repair hampered dose-specific investigations. We pooled data for 12 180 survivors (8339 from the Childhood Cancer Survivor Study and 3841 from the St Jude Lifetime Cohort) to estimate associations between deleterious homologous recombination repair variants and RT-related subsequent neoplasms (most commonly breast cancer, meningioma, thyroid cancer, and sarcoma) using conditional logistic regression with matched controls. In all, 1253 (10.3%) survivors were homologous recombination repair variant carriers, and 1301 (10.7%) developed at least 1 RT-related subsequent neoplasms. Variants increased the risk of out-of-field RT-related subsequent neoplasms (cases, 40/190 [21.1%]; control individuals, 9.7%; odds ratio [OR] = 2.5, 95% confidence interval [CI] = 1.7 to 3.6; P = 4.80 ×10−6), with consistent results across cohorts (Childhood Cancer Survivor Study, OR = 2.5, 95% CI = 1.6 to 3.7, P = 3.77 ×10−5; St Jude Lifetime Cohort, OR = 2.5, 95% CI = 1.0 to 6.4, P = 3.07 ×10−2). No association was observed for in-field or near-field subsequent neoplasms or individuals not undergoing RT. Findings emphasize homologous recombination repair variant-conferred susceptibility to RT-related subsequent neoplasms and dose-dependent DNA damage repair.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationRecombinational DNA RepairNeoplasms, Radiation-InducedNeoplasms, Second PrimaryHumansFemaleChildMaleThyroid NeoplasmsAdolescentSarcomaMeningiomaCase-Control StudiesAdultSurvivorsLogistic ModelsYoung AdultChild, PreschoolRisk

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, United States.
  • Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, United States.

ORCID-Profile: Shahriar A Zamani, Danielle M Karyadi, Stephen W Hartley, Todd M Gibson, Joshua N Sampson, Peter Kraft, Stephen J Chanock, Lindsay M Morton

Förderung

  • NCI NIH HHS
  • Cancer Center Support Grants
  • US Department of Health and Human Services
  • American Lebanese Syrian Associated Charities
  • HHS
  • National Institutes of Health (NIH)
  • NIH
  • NCI

Zitieren

APA

Zamani, S. A., Karyadi, D. M., Hartley, S. W., Gibson, T. M., Sampson, J. N., Kraft, P., Chanock, S. J., & Morton, L. M. (2026). Homologous recombination repair germline variants and subsequent neoplasm risk among childhood cancer survivors. JNCI Cancer Spectrum, 10(3). https://doi.org/10.1093/jncics/pkag030

Vancouver

Zamani SA, Karyadi DM, Hartley SW, Gibson TM, Sampson JN, Kraft P, et al. Homologous recombination repair germline variants and subsequent neoplasm risk among childhood cancer survivors. JNCI Cancer Spectrum. 2026;10(3). doi:10.1093/jncics/pkag030

BibTeX
@article{Zamani2026,
  author = {Zamani, Shahriar A and Karyadi, Danielle M and Hartley, Stephen W and Gibson, Todd M and Sampson, Joshua N and Kraft, Peter and Chanock, Stephen J and Morton, Lindsay M},
  title = {Homologous recombination repair germline variants and subsequent neoplasm risk among childhood cancer survivors},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.1093/jncics/pkag030}
}
Kostenlos starten →